Q-omics provides the consensus-scored NALCN-AS1 profile across patient tissues and cancer cell-line models. NALCN-AS1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NALCN-AS1 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, NALCN-AS1 RNA expression shows 11,908 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUSC, and THYM as cancer lineages where NALCN-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NALCN-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NALCN-AS1 survival associations across molecular data types. NALCN-AS1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NALCN-AS1 RNA expression–survival associations across cancer types. High NALCN-AS1 expression shows unfavorable associations in KIRC, BLCA, KICH, UVM and HNSC, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NALCN-AS1 RNA expression.
This table summarizes NALCN-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NALCN-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NALCN-AS1 shows lower tumor expression in LUSC, LUAD and BLCA and higher tumor expression in HNSC, CHOL and READ. The LUSC box plot shows higher NALCN-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.533, t-test p < 0.001).
This table shows molecular features associated with NALCN-AS1 in patient tissues and cancer cell lines. In patient samples, NALCN-AS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
